Scarica l'app Stockscreener
11.85
0.85%
0.10
Dopo l'orario di chiusura:
11.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$11.75
Aprire:
$11.75
Volume 24 ore:
3.48M
Relative Volume:
0.61
Capitalizzazione di mercato:
$8.09B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
2.0973
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+3.13%
1M Prestazione:
+4.31%
6M Prestazione:
+12.22%
1 anno Prestazione:
+4.77%
Intervallo 1D:
$11.68
$11.91
Intervallo di 1 settimana:
$10.90
$12.12
Portata 52W:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.85 | 8.02B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Price Consolidation Hints at Upcoming Move in Roivant Sciences Ltd.Earnings Growth Report & Safe Swing Trade Setups - sundaytimes.kr
Roivant plans $500M new share repurchase as brepocitinib data readout nears - MSN
Roivant’s High-Stakes Pipeline Bets On Biotech Breakthroughs - Finimize
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. Approaches Psychological Resistance Level2025 Big Picture & Weekly Market Pulse Alerts - 선데이타임즈
Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Just Slashed This Year's Revenue Estimates By 17% - 富途牛牛
Roivant Sciences’ (ROIV) Aggressive Buybacks Amid Losses: Commitment to Shareholders or Growth Uncertainty? - simplywall.st
Roivant Sciences Earnings Call: Progress Amid Challenges - TipRanks
Why Roivant Sciences Stock Bounced Back on Tuesday - Mitrade
Roivant Sciences shares rise 2.91% intraday after announcing a $500 million share repurchase program. - AInvest
Chairman on Gubra CEO change: Henrik Blou wants to try something different - medwatch.com
Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count By Investing.com - Investing.com South Africa
Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count - Investing.com Australia
Roivant Sciences Q1 2025 Earnings Call Highlights: Strong Cash Position and Share Repurchase Amidst Legal and Market Challenges - AInvest
Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Why Roivant Sciences Ltd. stock attracts strong analyst attentionHyper-Growth Screener - classian.co.kr
Roivant Sciences Reports Q1 2025 Financial Results - TipRanks
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - GlobeNewswire
Why Roivant Sciences Stock Was Slipping on Monday - Mitrade
Roivant Sciences Sees Losses Grow But Investors Hold Steady - Finimize
Roivant Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Roivant Deepens Its Losses But Keeps Investors On Board - Finimize
Roivant Sciences Reports Q1 EPS of 33c, Revenue of $2.17M, and Initiates $1.5B Share Buyback Program - AInvest
A Glimpse of Roivant Sciences's Earnings Potential - 富途牛牛
Roivant Sciences Ltd. announces an Equity Buyback for $500 million worth of its shares. - MarketScreener
Roivant Sciences Completes Equity Buyback Plan with 19.59% of Shares Repurchased - AInvest
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - MarketScreener
Roivant's Q1 2025 Earnings Call: Unraveling the Contradictions in Brepo's DM Market Positioning and Efficacy Expectations - AInvest
Roivant Sciences Ltd. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Roivant Sciences Ltd., Q1 2026 Earnings Call, Aug 11, 2025 - MarketScreener
Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2025 - MarketScreener
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Sciences earnings missed by $0.08, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q1 Swings to Loss, Revenue Falls - MarketScreener
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln - MarketScreener
Roivant Sciences Ltd. (ROIV) Misses Q1 EPS by 8c - StreetInsider
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $2.2M, vs. FactSet Est of $7.3M - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q1 Net Loss $0.33 a Share, vs. FactSet Est of $0.28 Loss - MarketScreener
Will Roivant Sciences Ltd. outperform the marketAI Intraday Market Movement Prediction Tool - Newser
Will Roivant Sciences Ltd. see short term momentumStrong Buy Signal Summary with Entry Zone - Newser
How high can Roivant Sciences Ltd. stock goDaily Entry Opportunity Forecasting Tool - Newser
Roivant Sciences Ltd. Breaks Losing Streak — Is the Trend ReversingTrade Scanner With Buy Zone Alerts Flagged - metal.it
Is Roivant Sciences Ltd. stock a good hedge against inflationTechnical Reversal Pattern Summary and Tracker - Newser
Roivant Sciences Earnings Expectations: A Closer Look at the Company's Performance and Analyst Sentiments - AInvest
Roivant Sciences (ROIV) to Release Earnings on Monday - Defense World
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):